<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068780</url>
  </required_header>
  <id_info>
    <org_study_id>BEB-13</org_study_id>
    <secondary_id>2016-002066-32</secondary_id>
    <nct_id>NCT03068780</nct_id>
  </id_info>
  <brief_title>Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa</brief_title>
  <acronym>EASE</acronym>
  <official_title>Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amryt Research Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amryt Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited
      Epidermolysis Bullosa (EB).

      EB is a rare group of genetic skin fragility disorders characterised by blistering of the
      skin in response to minor injury. In most cases, onset of EB is at birth or shortly after.
      All participants affected by any type of EB share the main characteristic of repeatedly
      developing painful wounds that take days to months to heal. Current treatment of EB is
      primarily preventative and supportive including protection from mechanical forces by avoiding
      rubbing, early treatment of wounds to prevent infections, and protection of the wound with
      adequate non-adhesive dressings to enable healing.

      Oleogel-S10 was authorised in 2016 in the European Union for treatment of partial thickness
      wounds in adults under the brand name Episalvan®. The active pharmaceutical ingredient in
      Oleogel-S10 is a refined birch bark extract, quantified to 72 to 88% betulin.

      This clinical study of Oleogel-S10 in patients with inherited EB has been initiated to
      investigate whether Oleogel-S10 is effective for treatment of EB wounds and safe in the long
      term use.

      Oleogel-S10 will be compared to a vehicle gel placebo. The placebo is an identical looking
      sunflower oil gel that does not contain any active substance. The participant will receive
      either Oleogel-S10 or vehicle gel for a double-blind study phase of 90 days. The probability
      that the participant will receive Oleogel-S10 is 50%, which means that they have a 1 in 2
      chance of receiving Oleogel-S10. However, in the follow-up phase of the study all
      participants will be treated with Oleogel S10 for a period of 24 months.

      This clinical study will be performed in several countries; in total, about 164 participants
      are expected to participate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with first complete closure of the EB target wound within 45 days of treatment</measure>
    <time_frame>45±7 days</time_frame>
    <description>Proportion of patients with first complete closure of the EB target wound (defined as EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days) within 45±7 days of treatment with Oleogel-S10 compared to placebo based on clinical assessment by the investigator (the wound will be rated as &quot;closed&quot; at first appearance of complete reepithelialisation without drainage confirmed by a second observation within the following week)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first complete closure of the EB target wound as evidenced by clinical assessment until Day 90±7.</measure>
    <time_frame>90±7 days</time_frame>
    <description>Time to first complete closure of the EB target wound (defined as EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days) within 90±7 days of treatment with Oleogel-S10 compared to placebo based on clinical assessment by the investigator (the wound will be rated as &quot;closed&quot; at first appearance of complete reepithelialisation without drainage confirmed by a second observation within the following week)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <arm_group>
    <arm_group_label>Oleogel-S10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oleogel-S10</intervention_name>
    <description>10% birch bark extract in 90% sunflower oil</description>
    <arm_group_label>Oleogel-S10</arm_group_label>
    <other_name>Episalvan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sunflower oil gel</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with any subtype of inherited EB including EB simplex (EBS),
             junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome age ≥4 years,

          -  Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm²
             in size aged ≥21 days),

          -  Patient and/or his/her legal representative has/have been informed, has/have read and
             understood the patient information/informed consent form, and has/have given written
             informed consent,

          -  Patient and/or his/her legal representative must be able and willing to follow study
             procedures and instructions.

        Exclusion Criteria:

          -  EB target wound with clinical signs of local infection,

          -  Use of systemic antibiotics for wound-related infections within 7 days prior to
             enrolment,

          -  Administration of systemic or topical steroids (except for inhaled, ophthalmic or
             topical applications, such as budesonide suspension for oesophageal strictures [e.g.,
             Pulmicort respules® 0.25 mg/2 mL or 0.5 mg/2 mL]) within 30 days before enrolment,

          -  Immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrolment,

          -  Patient has undergone stem cell transplant or gene therapy for the treatment of
             inherited EB,

          -  Current and/or former malignancy including basal cell carcinomas and squamous cell
             carcinomas,

          -  Enrolment in any interventional study or treated with any investigational drug for any
             disease within 4 weeks prior to study entry,

          -  Factors present in the patient and/or his/her legal representative that could
             interfere with study compliance such as inability to attend scheduled study visits or
             compliance with home dressing changes,

          -  Pregnant or nursing women and women of childbearing potential including postmenarchal
             female adolescents not willing to use an effective form of birth control with failure
             rates &lt;1% per year (e.g., implant, injectable, combined oral contraceptive,
             intrauterine contraceptive device, sexual abstinence, vasectomised partner) during
             participation in the study (and at least 3 months thereafter),

          -  Patient is a member of the investigational team or his/her immediate family,

          -  Patient lives in the same household as a study participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes S Kern, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Head of Clinical Development</last_name>
    <phone>+35316694606</phone>
    <email>easestudy@amrytpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Monitor, MD</last_name>
    <email>medicalmonitor@amrytpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Consutorios Medicos (Instituto de Neumonologia y Dermatologia)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+54 11 4821 5929</phone>
      <email>doctoralarralde@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Margarita Larralde, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Saad</last_name>
      <phone>+61430484799</phone>
      <email>rebecca.saad@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Orli Wargon, A/Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Specialists</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charmaine Peras</last_name>
      <phone>02 9598 5800</phone>
      <email>premierspecnurse@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dédée F. Murrell, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Phemister</last_name>
      <phone>03 9342 4531</phone>
      <email>Annette.Phemister@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Johannes Kern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Murdoch Childrens Research Institute Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3502</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Kokoszka</last_name>
      <phone>+61 3 9345 5570</phone>
      <email>Shannon.Kokoszka@rch.org.au</email>
    </contact>
    <investigator>
      <last_name>Susan Robertson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik fuer Dermatologie</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Kitzmueller</last_name>
      <phone>+43 57255-24601</phone>
      <email>s.kitzmueller@salk.at</email>
    </contact>
    <investigator>
      <last_name>Martin Laimer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tine Vanhoutvin</last_name>
      <email>marie-anne.morren@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Marie-Anne Morren, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Debra Chile</name>
      <address>
        <city>Santiago</city>
        <zip>7760099</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacia Fuentes</last_name>
      <phone>+56 9-9310 8821</phone>
      <email>ignacia.fuentesbustos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francis Palisson, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De San Jose</name>
      <address>
        <city>Bogotá</city>
        <state>DC</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elda Carolina Pena</last_name>
      <phone>+57 1 3538000</phone>
    </contact>
    <investigator>
      <last_name>Mauricio Torres, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+385 012368 915</phone>
    </contact>
    <investigator>
      <last_name>Branka Marinovic, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno, Children´s Hospital</name>
      <address>
        <city>Brno</city>
        <zip>61500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+42 532 234 521</phone>
      <email>buckova.hana@fnbrno.cz</email>
    </contact>
    <investigator>
      <last_name>Hana Buckova, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Mette Thorup, Dr.</last_name>
      <email>metsom@rm.dk</email>
    </contact>
    <investigator>
      <last_name>Mette Sommerlund, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>6200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 492039211</phone>
      <email>chiaverini.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Chiaverini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhia Wiam</last_name>
      <phone>+33 144494672</phone>
    </contact>
    <investigator>
      <last_name>Christine Bodemer, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hospital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Hoareau</last_name>
      <phone>+33 567778121</phone>
      <email>mazereeuw-hautier.j@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Juliette Mazereeuw-Hautier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center University Freiburg</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelia Winter</last_name>
      <phone>+49 76127067141</phone>
      <email>aurelia.winter@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Franziska Schauer, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugendkrankenhaus AUF DER BULT</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aschemier, Dr.</last_name>
      <phone>+49 51181156611</phone>
      <email>aschemeier@hka.de</email>
    </contact>
    <investigator>
      <last_name>Hagen Ott, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hautklinik Kiel, UKSH, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Gertz</last_name>
      <phone>+49 4315971579</phone>
      <email>mgertz@dermatology.uni-kiel.de</email>
    </contact>
    <investigator>
      <last_name>Regina Foelster-Holst, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Skin and Veneral Diseases &quot;A. Syggros&quot;</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>16121</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioanna Verroiou, Dr.</last_name>
      <phone>+30 2107265130</phone>
      <email>alkats.duoa@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Alexandra Katsarou-Katsari, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmine Yu</last_name>
      <phone>+852 3505 1124</phone>
      <email>jasminewsyu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ellis Hon Kam Lun, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Faculty of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sillo Palma, Dr.</last_name>
      <phone>+36 20 825 8878</phone>
      <email>sillo.palma@med.semmelweis-univ.hu</email>
    </contact>
    <investigator>
      <last_name>Miklos Sardy, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St James Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Richardson</last_name>
      <phone>+353 1 410 3903</phone>
      <email>JARICHAR@tcd.ie</email>
    </contact>
    <investigator>
      <last_name>Fiona Browne, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Ladys Childrens Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann-Marie Day</last_name>
      <phone>+353 1 4096444</phone>
      <email>annmarie.day@ncrc.ie</email>
    </contact>
    <investigator>
      <last_name>Fiona Browne, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dvora Cohen</last_name>
      <phone>+972 36974287</phone>
      <email>elisp@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Eli Sprecher, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilaria Coro</last_name>
      <phone>+39 0255032450</phone>
      <email>paola.marchisio@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Paola Marchisio, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bambino Gesù Children Hospital</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Simonetti, Dr.</last_name>
      <phone>+39 0668592509</phone>
      <email>andrea.diociaiuti@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Andrea Diociaiuti, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Dermopatico dell'Immacolata IDI-IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Guerra</last_name>
      <phone>+39 0666462010</phone>
      <email>b.didona@idi.it</email>
    </contact>
    <investigator>
      <last_name>Biagio Didona, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kandang Kerbau (KK) Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Pui Yoong Ho, Dr.</last_name>
      <email>valerie.ho.p.y@singhealth.com.sg</email>
    </contact>
    <investigator>
      <last_name>Mark Jean Aan Koh, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Barranco</last_name>
      <phone>+34 934893475</phone>
    </contact>
    <investigator>
      <last_name>Elena Arana, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vega Mauleon</last_name>
      <phone>+34 912 071 876</phone>
      <email>vegamauleon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Raul De Lucas, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Wienand</last_name>
      <phone>+41 316326983</phone>
      <email>mark.wienand@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Carolina Gouveia, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital NHS Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Lynne</last_name>
      <phone>+44 1213339999</phone>
      <email>victoria.lynne@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Malobi Ogboli, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Holland</last_name>
      <phone>+44 2077626892</phone>
      <email>Lauren.Holland@gosh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anna Martinez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

